| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 14.01 | 0.20 (+1.45%) | 8.80 - 14.92 | 12.7 thousand (Below Avg) |
Market data as of 4:00PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 13.81 |
|---|---|
| Previous Close | 13.81 |
| Day's Range | 13.67 - 14.05 |
| Market Cap | 237.8M |
| Avg Volume (10 Day) | 24.4K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.13 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Derma Sciences Appoints Medical Device Veteran Amy S. Paul to Its Board of Directors
Business Wire - Friday 05/24/2013 10:49 AM ET
Derma Sciences Reports First Quarter 2013 Financial Results
Business Wire - Thursday 05/16/2013 7:30 AM ET
Derma Sciences Engages Plexus Ventures to Explore Strategic Options for DSC127 Outside the U.S.
Business Wire - Tuesday 05/14/2013 7:30 AM ET
Derma Sciences to Hold First Quarter Financial Results Conference Call on May 16th
Business Wire - Tuesday 05/07/2013 7:30 AM ET
Derma Sciences Begins Screening Patients in Second Phase 3 Trial with DSC127 for Healing Diabetic Foot Ulcers
Business Wire - Thursday 04/25/2013 4:01 PM ET
| DSCI | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 19.87% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 3.12 |
| Company | Last | Change |
|---|---|---|
| Nanosphere Inc | 4.26 | +12.40% |
| OraSure Technologies Inc | 4.34 | -1.59% |
| Vascular Solutions Inc | 15.09 | +0.94% |
| AtriCure Inc | 9.28 | -0.22% |
| Alphatec Holdings Inc | 1.95 | +0.52% |
Data is delayed by at least 15 min.